Harbor Investment Advisory LLC Invests $52,000 in RxSight, Inc. (NASDAQ:RXST)

Harbor Investment Advisory LLC acquired a new position in RxSight, Inc. (NASDAQ:RXST) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 1,502 shares of the company’s stock, valued at approximately $52,000.

Other institutional investors have also made changes to their positions in the company. Nisa Investment Advisors LLC increased its stake in shares of RxSight by 854.1% in the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after purchasing an additional 521 shares during the period. Quarry LP increased its stake in shares of RxSight by 82.3% in the third quarter. Quarry LP now owns 638 shares of the company’s stock worth $32,000 after purchasing an additional 288 shares during the period. Point72 Hong Kong Ltd bought a new position in RxSight during the third quarter valued at about $34,000. KBC Group NV increased its stake in RxSight by 63.6% during the third quarter. KBC Group NV now owns 1,232 shares of the company’s stock valued at $61,000 after acquiring an additional 479 shares during the period. Finally, Amalgamated Bank increased its stake in RxSight by 21.3% during the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after acquiring an additional 207 shares during the period. 78.78% of the stock is currently owned by institutional investors.

RxSight Trading Up 3.0 %

NASDAQ RXST opened at $31.91 on Thursday. The stock’s 50 day moving average is $38.10 and its two-hundred day moving average is $46.15. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -38.45 and a beta of 1.20. RxSight, Inc. has a 1-year low of $26.29 and a 1-year high of $66.54.

RxSight (NASDAQ:RXST) last announced its earnings results on Thursday, November 7th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.18). The business had revenue of $35.31 million during the quarter, compared to analyst estimates of $35.15 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. During the same period in the previous year, the firm earned ($0.35) earnings per share. On average, analysts predict that RxSight, Inc. will post -0.7 earnings per share for the current year.

Insider Transactions at RxSight

In other RxSight news, Director Jesse Anderson Corley bought 1,443 shares of RxSight stock in a transaction dated Wednesday, January 15th. The shares were acquired at an average cost of $31.18 per share, with a total value of $44,992.74. Following the acquisition, the director now directly owns 1,443 shares of the company’s stock, valued at $44,992.74. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $50.64, for a total value of $156,984.00. Following the completion of the transaction, the insider now directly owns 42,246 shares in the company, valued at $2,139,337.44. The trade was a 6.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 31,697 shares of company stock valued at $1,495,941 in the last three months. 9.36% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on RXST. Stifel Nicolaus lowered their price target on RxSight from $40.00 to $35.00 and set a “hold” rating on the stock in a research note on Monday, January 13th. Jefferies Financial Group began coverage on RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target on the stock. Wells Fargo & Company lowered their price target on RxSight from $42.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. UBS Group began coverage on RxSight in a research note on Friday, December 6th. They set a “buy” rating and a $52.00 price target on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $66.00 price target on shares of RxSight in a research note on Monday, January 13th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $58.13.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.